

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The results of the ET743-SAR-3007 trial comparing trabectedin to dacarbazine in patients with previously treated advanced liposarcoma or leiomyosarcoma reported a statistically significant improvement in \_\_\_\_\_ with trabectedin.

  - a. Progression-free survival
  - b. Overall survival
  - c. Both a and b
2. A Phase III trial of eribulin versus dacarbazine in previously treated advanced or metastatic STS demonstrated that the benefit in overall survival with eribulin was greater in patients with which histology?

  - a. Liposarcoma
  - b. Leiomyosarcoma
3. Which of the following agents are FDA approved for patients with liposarcomas?

  - a. Eribulin
  - b. Trabectedin
  - c. Regorafenib
  - d. All of the above
  - e. Both a and b
4. The randomized Phase II JGDG trial investigating the addition of olaratumab to doxorubicin versus doxorubicin alone for patients with advanced or metastatic STS demonstrated a statistically significant improvement in \_\_\_\_\_ with the combination.

  - a. Overall survival
  - b. Progression-free survival
  - c. Both a and b
5. Side effects associated with trabectedin include \_\_\_\_\_.

  - a. Liver function abnormalities
  - b. Myelosuppression
  - c. Rhabdomyolysis
  - d. All of the above
6. The EORTC 62931 study evaluating the efficacy of adjuvant chemotherapy for patients with high-risk STS reported an improvement in overall and disease-free survival with adjuvant chemotherapy.

  - a. True
  - b. False
7. The Phase II REGOSARC trial assessing the efficacy of regorafenib versus placebo for patients with previously treated advanced STS demonstrated a benefit in progression-free survival in which group of patients?

  - a. Patients with liposarcoma
  - b. Patients with nonadipocytic STS
  - c. Both a and b
8. Olaratumab, an agent recently approved for STS, is a(n) \_\_\_\_\_.

  - a. Immune checkpoint inhibitor
  - b. Tyrosine kinase inhibitor
  - c. Monoclonal antibody to PDGFR $\alpha$
9. Results from the Phase II SARCO28 trial investigating the safety and efficacy of \_\_\_\_\_ in patients with advanced sarcomas demonstrated promising activity in patients with undifferentiated pleomorphic sarcoma and liposarcoma.

  - a. Pembrolizumab
  - b. Nivolumab
  - c. Nivolumab with ipilimumab
10. A recent study by Gronchi and colleagues evaluating the efficacy of neoadjuvant chemotherapy for patients with high-risk STS reported a benefit in overall survival in patients randomly assigned to the epirubicin/ifosfamide arm versus those who received a histologically tailored regimen.

  - a. True
  - b. False